.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Moodys
Healthtrust
McKesson
Julphar
Merck
Deloitte
Fuji
Citi

Generated: June 26, 2017

DrugPatentWatch Database Preview

ACTOS Drug Profile

« Back to Dashboard

Which patents cover Actos, and what generic Actos alternatives are available?

Actos is a drug marketed by Takeda Pharms Usa and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-one patent family members in twenty-five countries.

The generic ingredient in ACTOS is pioglitazone hydrochloride. There are twenty-seven drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the pioglitazone hydrochloride profile page.

Summary for Tradename: ACTOS

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list11
Bulk Api Vendors: see list73
Clinical Trials: see list68
Patent Applications: see list2,024
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ACTOS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-001Jul 15, 1999ABRXYesNo6,303,640► Subscribe ► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-002Jul 15, 1999ABRXYesNo6,303,640► Subscribe ► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-003Jul 15, 1999ABRXYesYes6,303,640► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ACTOS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-002Jul 15, 19994,687,777► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-002Jul 15, 19995,965,584► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-002Jul 15, 19996,329,404► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-001Jul 15, 19996,150,383► Subscribe
Takeda Pharms Usa
ACTOS
pioglitazone hydrochloride
TABLET;ORAL021073-001Jul 15, 19996,303,640► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ACTOS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,169,099 Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,225,326 Pharmaceutical composition► Subscribe
6,103,742 Pharmaceutical composition► Subscribe
6,156,773 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ACTOS

Country Document Number Estimated Expiration
Hungary9601698► Subscribe
Slovakia287351► Subscribe
Portugal861666► Subscribe
European Patent Office2289556► Subscribe
South Korea20080005162► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ACTOS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C026/2009Ireland► SubscribeSPC026/2009: 20101001, EXPIRES: 20210619
C 038/2006Ireland► SubscribeSPC 038/2006: 20070528, EXPIRES: 20210619
298Luxembourg► Subscribe91298, EXPIRES: 20210620
2009 00045Denmark► Subscribe
C/GB07/009United Kingdom► SubscribeSPC/GB07/009: 20070126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Teva
Queensland Health
Boehringer Ingelheim
QuintilesIMS
Medtronic
Cantor Fitzgerald
Fish and Richardson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot